Evidence map›Paper›PMID 38763995›Full record

ReviewJournal of nephrology2024

A practical approach to implementing incremental haemodialysis.

Usama Butt, A Davenport, S Sridharan, K Farrington, E Vilar

Abstract readReview
PubMed Publisher
In one paragraph

Review in Journal of nephrology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Guideline
  2. Article
  3. Article
  4. Green, Sustainable Nephrology: State of the Art Needs for Education and Implementation.Clinical journal of the American Society of Nephrology : CJASN · 2025
    Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Usama ButtRenal Unit, Lister Hospital, East and North Herts NHS Trust, Hertfordshire, SG1 4AB, UK. usama.butt1@nhs.net.
A DavenportRoyal Free Hospital, Royal Free London Foundation Trust, London, UK.ORCID 0000-0002-4467-6833
S SridharanRenal Unit, Lister Hospital, East and North Herts NHS Trust, Hertfordshire, SG1 4AB, UK.
K FarringtonRenal Unit, Lister Hospital, East and North Herts NHS Trust, Hertfordshire, SG1 4AB, UK.
E VilarRenal Unit, Lister Hospital, East and North Herts NHS Trust, Hertfordshire, SG1 4AB, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The majority of end-stage kidney disease patients are treated with haemodialysis (HD). Starting HD can pose physical, social, and psychological challenges to patients, and mortality rates within the first 6 months are disproportionately high, with intensive HD regimens implicated as a potential factor. Starting HD with an incremental approach, taking residual kidney function (RKF) into account, potentially allows for a gentle start with reduced dialysis intensity. Dialysis intensity (session time or frequency) can then be proportionally increased as RKF reduces. This approach to starting HD has been reported in observational studies to result in better patient self-reported health quality of life and reduced costs, and now several definitive randomised controlled trials are underway comparing an incremental approach to the conventional thrice weekly paradigm. Physician concerns over the risk of inadequate dialysis, with consequent increased emergency admissions, and practical challenges of how to estimate RKF and implement incremental dialysis have impeded widespread adoption. Addressing these challenges is paramount to increasing the uptake of incremental HD. Careful patient selection lies at the heart of a successful incremental HD programme. Generally, patients with a residual urea clearance of > 3 ml/min/1.73 m

Indexed as

Kidney Failure, ChronicRenal DialysisHumansKidneyPatient SelectionQuality of LifeDialysisGuideHemodialysisIncrementalIndividualizationPractical

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.